Shaji K. Kumar
Mayo Clinic in Rochester · Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shaji K. Kumar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:42 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06151717 · A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple MyelomaMayo Clinic · completed · Multiple Myeloma · principal investigator
- Ph1NCT06042725 · MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaMayo Clinic · active not recruiting · Multiple Myeloma · principal investigator
- N/ANCT05918185 · Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple MyelomaMayo Clinic · completed · Plasma Cell Myeloma · principal investigator
- Ph2NCT05497804 · Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialMayo Clinic · active not recruiting · ISS Stage III Plasma Cell Myeloma, Multiple Myeloma · principal investigator
- Ph1NCT04892264 · Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple MyelomaMayo Clinic · terminated · Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph3NCT04566328 · Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialECOG-ACRIN Cancer Research Group · recruiting · Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Ph3NCT03941860 · Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM TrialNational Cancer Institute (NCI) · completed · Multiple Myeloma
- Ph2NCT03841565 · Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaAcademic and Community Cancer Research United · withdrawn · Recurrent Plasma Cell Myeloma
- Ph2NCT01415882 · Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to BortezomibMayo Clinic · completed · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph1/Ph2NCT01049945 · Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaMayo Clinic · completed · Refractory Multiple Myeloma · study chair
- Ph1/Ph2NCT01034553 · Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaMayo Clinic · completed · Refractory Multiple Myeloma · principal investigator
- Ph2NCT00772915 · Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaMayo Clinic · completed · Multiple Myeloma and Plasma Cell Neoplasm · study chair
- Ph1NCT00687674 · Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaMayo Clinic · terminated · Multiple Myeloma and Plasma Cell Neoplasm · study chair
- Ph2NCT00635024 · Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple MyelomaMayo Clinic · terminated · Multiple Myeloma and Plasma Cell Neoplasm · study chair
- Ph2NCT00564889 · Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisMayo Clinic · completed · Multiple Myeloma and Plasma Cell Neoplasm · study chair
- Ph2NCT00478218 · Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaMayo Clinic · completed · Multiple Myeloma and Plasma Cell Neoplasm · study chair
- Ph1/Ph2NCT00474929 · Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaMayo Clinic · completed · Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Impact of Genetic susceptibility along the continuum from MGUS to MMU01CA271014 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2022 to 2026 · $617,059 awarded in 2026Same name and institution; not confirmed by an ID
- Onset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2012 to 2024 · $78,948 awarded in 2024Same name and institution; not confirmed by an ID
- Clinical Protocol and Data ManagementP30CA015083 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2019 to 2022 · $558,028 awarded in 2022Grant number is on one of their registry trials
- Project 2 - IMiD Resistance in Patients and Humanized Mice with Multiple MyelomaU54CA224018 · NCI · MAYO CLINIC ARIZONA · fiscal years 2019 to 2021 · $314,462 awarded in 2021Same name and institution; not confirmed by an ID
- Prevalence and Progression of Monoclonal GammopathiesR01CA107476 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2014 to 2018 · $321,975 awarded in 2018Same name and institution; not confirmed by an ID
- The Role of Cereblon Pathways in MyelomaR01CA183968 · NCI · MAYO CLINIC ARIZONA · fiscal years 2014 to 2018 · $446,267 awarded in 2018Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Biostatistics and Bioinformatics CoreP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Amylou Constance Dueck · fiscal years 2015 to 2026Named on NCT05497804
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT04566328, NCT03941860
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:42 UTC. The ranking covers the 200 most relevant of 66 PubMed records, and a shared surname and initials can bring in a namesake. All 66 on PubMed
- 348 citationsRCR 14.4
- 337 citationsRCR 19.3
- Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease.Transl Res · 2010293 citationsRCR 8.3
- 271 citationsRCR 11.9
- 232 citationsRCR 10.3
- 228 citationsRCR 6.4
- Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.Nat Med · 2023227 citationsRCR 17.2
- 217 citationsRCR 8.5
- 212 citationsRCR 6.0
- The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.Blood · 2007208 citationsRCR 5.2